What types of infections does Rocephin (ceftriaxone) cover?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Rocephin (Ceftriaxone) Coverage

Rocephin covers a broad spectrum of bacterial infections including respiratory tract infections, skin/soft tissue infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, septicemia, bone/joint infections, intra-abdominal infections, meningitis, and is used for surgical prophylaxis 1.

Specific Infection Types and Causative Organisms

Respiratory Tract Infections

  • Lower respiratory tract infections caused by:
    • Streptococcus pneumoniae
    • Staphylococcus aureus
    • Haemophilus influenzae and H. parainfluenzae
    • Klebsiella pneumoniae
    • Escherichia coli
    • Enterobacter aerogenes
    • Proteus mirabilis
    • Serratia marcescens 1

Ear Infections

  • Acute bacterial otitis media caused by:
    • Streptococcus pneumoniae
    • Haemophilus influenzae (including beta-lactamase producing strains)
    • Moraxella catarrhalis (including beta-lactamase producing strains) 1

Skin and Soft Tissue Infections

Covers a wide range of pathogens including:

  • Staphylococcus aureus and S. epidermidis
  • Streptococcus pyogenes and Viridans group streptococci
  • Gram-negative organisms: E. coli, Enterobacter cloacae, Klebsiella species, Proteus mirabilis, Morganella morganii
  • Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus
  • Anaerobes: Bacteroides fragilis, Peptostreptococcus species 1

Urinary Tract Infections

  • Both complicated and uncomplicated UTIs caused by:
    • Escherichia coli
    • Proteus mirabilis and P. vulgaris
    • Morganella morganii
    • Klebsiella pneumoniae 1

Sexually Transmitted Infections

  • Uncomplicated gonorrhea (cervical/urethral and rectal):
    • Neisseria gonorrhoeae (both penicillinase and non-penicillinase producing strains)
    • Pharyngeal gonorrhea (non-penicillinase producing strains only)
  • Pelvic inflammatory disease caused by N. gonorrhoeae 1

Critical caveat: Ceftriaxone has NO activity against Chlamydia trachomatis, so appropriate antichlamydial coverage must be added when treating PID 1.

Septicemia

  • Bacterial septicemia caused by:
    • Staphylococcus aureus
    • Streptococcus pneumoniae
    • Escherichia coli
    • Haemophilus influenzae
    • Klebsiella pneumoniae 1

Bone and Joint Infections

Covers:

  • Staphylococcus aureus
  • Streptococcus pneumoniae
  • Escherichia coli
  • Proteus mirabilis
  • Klebsiella pneumoniae
  • Enterobacter species 1

Intra-Abdominal Infections

For mild to moderate community-acquired intra-abdominal infections, ceftriaxone combined with metronidazole is a first-line option 2. Covers:

  • Escherichia coli
  • Klebsiella pneumoniae
  • Bacteroides fragilis
  • Clostridium species (most C. difficile strains are resistant)
  • Peptostreptococcus species 1

Central Nervous System Infections

  • Meningitis caused by:
    • Haemophilus influenzae
    • Neisseria meningitidis
    • Streptococcus pneumoniae
    • Limited success with Staphylococcus epidermidis and E. coli in meningitis/shunt infections 1

Surgical Prophylaxis

Single 1g dose preoperatively reduces postoperative infections in:

  • Contaminated or potentially contaminated procedures (vaginal/abdominal hysterectomy, cholecystectomy)
  • High-risk surgical patients
  • Coronary artery bypass surgery 1

Important Limitations

Pseudomonas Coverage

Ceftriaxone has minimal activity against Pseudomonas aeruginosa and cannot be recommended as sole therapy for pseudomonal infections 3, 4. While it may have some in vitro activity, clinical efficacy is inadequate for monotherapy.

Enterococcal Coverage

When using ceftriaxone for intra-abdominal infections, ampicillin should be added if enterococcal coverage is needed, as ceftriaxone does not adequately cover enterococcus 2.

MRSA

Ceftriaxone has no activity against methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin must be added if MRSA is suspected 2.

Clinical Context

The FDA labeling emphasizes that culture and susceptibility testing should guide therapy when available 1. In the absence of such data, local epidemiology and resistance patterns should inform empiric selection. Ceftriaxone's broad Gram-negative coverage generally exceeds first and second-generation cephalosporins, though its Gram-positive coverage is somewhat less robust than earlier cephalosporins 3.

References

Related Questions

Is the intravenous (IV) and intramuscular (IM) ceftriaxone dose the same in pediatric patients?
When should ceftriaxone be administered by injection (intravenous infusion or deep intramuscular) and what are the appropriate indications?
What is the recommended treatment and dosage of Ceftriaxone for bacterial infections in adults with varying degrees of renal function and different types of infections?
What are the recommended administration routes, dosing, and dilution guidelines for ceftriaxone?
In a 30‑year‑old man with a 1‑day purulent folliculitis on the inner left thigh, is a single 1 g intramuscular dose of ceftriaxone (Rocephin) sufficient, and should I prescribe oral augmentin (amoxicillin‑clavulanate) or trimethoprim‑sulfamethoxazole double‑strength for MRSA coverage?
What is the mechanism of action and pathophysiology of aspirin?
How does quetiapine affect sleep architecture in healthy adults?
What are the indications for MRI in a patient with lower back pain?
Are there reported cases of multiple nevus depigmentosus lesions involving the perioral region, infra‑orbital (under‑eye) area, and neck?
When is a head CT indicated for a patient with dizziness who is being evaluated for a possible intracranial aneurysm?
In an outpatient 14-year-old with two days of right lower quadrant pain and mild nausea, which imaging study is preferred: abdominal ultrasound or contrast-enhanced CT?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.